Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Total Debt (2022 - 2025)

Historic Total Debt for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $109.1 million.

  • BioXcel Therapeutics' Total Debt rose 448.58% to $109.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.1 million, marking a year-over-year increase of 448.58%. This contributed to the annual value of $102.5 million for FY2024, which is 189.86% up from last year.
  • According to the latest figures from Q3 2025, BioXcel Therapeutics' Total Debt is $109.1 million, which was up 448.58% from $108.7 million recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Total Debt peaked at $109.1 million during Q3 2025, and registered a low of $56000.0 during Q1 2022.
  • For the 4-year period, BioXcel Therapeutics' Total Debt averaged around $91.7 million, with its median value being $100.6 million (2023).
  • In the last 5 years, BioXcel Therapeutics' Total Debt surged by 17033214.29% in 2023 and then skyrocketed by 189.86% in 2024.
  • BioXcel Therapeutics' Total Debt (Quarter) stood at $93.5 million in 2022, then rose by 7.62% to $100.6 million in 2023, then rose by 1.9% to $102.5 million in 2024, then rose by 6.46% to $109.1 million in 2025.
  • Its last three reported values are $109.1 million in Q3 2025, $108.7 million for Q2 2025, and $105.5 million during Q1 2025.